| Key Facts • GLP-1 weight loss medications like Wegovy and Zepbound are FDA-approved for chronic weight management but are excluded from many insurance plans. • Coverage depends on your plan type: employer-sponsored, Medicare, Medicaid, or marketplace insurance. • Most plans that do cover these drugs require prior authorization, a BMI of 30 or higher (or 27+ with a weight-related condition), and documented diet and exercise attempts. • As of 2026, coverage is expanding — but significant gaps remain. Your physician can help you navigate the process. • Core Primary Care offers physician-supervised medical weight loss at locations in Houston, Sugar Land, Katy, and Needville TX. |
If you have been trying to find out whether your insurance covers weight loss medication, you are not alone. Millions of Americans have the same question — and the answer is more complicated than a simple yes or no. Coverage for weight loss drugs varies significantly by insurer, plan type, employer, and the specific medication prescribed.
The good news: coverage is improving. In 2026, more insurers and employer health plans are adding GLP-1 weight loss medications to their formularies, driven by growing clinical evidence and pressure from employers managing workforce health costs. The bad news: many plans still explicitly exclude weight loss drugs, and the rules around prior authorization, BMI thresholds, and step therapy requirements can make the process frustrating without physician guidance.
This guide explains what is covered, which plans are most likely to cover GLP-1 medications like Wegovy and Zepbound, what criteria you typically need to meet, and how to work with your care provider to improve your chances of approval. Patients at Core Primary Care in Houston, Sugar Land, Katy, and Needville can work directly with our physicians to navigate insurance coverage and access the weight management treatment that is right for them.
| Quick Clinical Answer: Are Weight Loss Drugs Covered by Insurance? Some insurance plans cover FDA-approved weight loss medications, but coverage is inconsistent. GLP-1 drugs like Wegovy and Zepbound are covered by a growing number of employer health plans and select Medicaid programs, but remain excluded from standard Medicare Part D and many marketplace plans. Eligibility typically requires a BMI of 30 or higher, or 27 or higher with an obesity-related condition such as type 2 diabetes or high blood pressure. Prior authorization is almost always required. |
Which Weight Loss Medications Are Covered by Insurance?
Not all weight loss drugs carry equal coverage. Insurance plans distinguish between older oral medications — such as phentermine, Contrave, and Qsymia — and the newer injectable GLP-1 weight loss medications that have dominated the market since 2021. The coverage landscape for each category is very different.
Older oral medications like Contrave and Qsymia are on more plan formularies because they have been available longer and carry lower per-prescription costs. Injectable GLP-1 medications, by contrast, carry list prices in the range of $1,000 to $1,400 per month, which has made insurers and employers cautious about adding them to their formularies without strict clinical criteria.
The FDA-approved weight loss drugs most commonly discussed in insurance contexts in 2026 are:
| Medication | Drug Type | FDA Approval | Typical Coverage Status |
| Wegovy (semaglutide) | GLP-1 injectable | Chronic weight management | Covered by select employer plans; limited Medicaid |
| Zepbound (tirzepatide) | GIP/GLP-1 injectable | Chronic weight management | Growing employer coverage; limited Medicaid |
| Ozempic (semaglutide) | GLP-1 injectable | Type 2 diabetes (off-label for weight loss) | Widely covered for T2D; variable for weight loss |
| Mounjaro (tirzepatide) | GIP/GLP-1 injectable | Type 2 diabetes (off-label for weight loss) | Covered for T2D; often excluded for weight loss only |
| Contrave (naltrexone/bupropion) | Oral combination | Chronic weight management | More frequently covered; lower cost |
| Qsymia (phentermine/topiramate) | Oral combination | Chronic weight management | Moderate coverage; formulary varies |
Note: Ozempic and Mounjaro are approved by the Food and Drug Administration for type 2 diabetes management, not weight loss specifically. Insurers typically cover them for diabetes, but coverage for weight loss as a standalone indication is far less consistent. Wegovy and Zepbound — the branded versions of the same active ingredients (semaglutide and tirzepatide, respectively) dosed specifically for obesity — carry separate FDA approval for chronic weight management and are the medications most often at the center of insurance coverage debates.
GLP-1 Insurance Coverage: What You Need to Know
GLP-1 receptor agonists are the most clinically significant advance in obesity treatment in decades. Semaglutide (Wegovy) produced an average body weight reduction of approximately 15% in the STEP 1 trial (Wilding et al., NEJM 2021). Tirzepatide (Zepbound) showed even greater results in the SURMOUNT-1 trial. Despite that evidence, GLP-1 insurance coverage remains one of the most inconsistent areas in health insurance in 2026.
The core problem is cost. Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy carry list prices that make insurers treat them differently from most other prescription drugs. Many insurers have responded by either excluding these medications outright or placing them on the highest formulary tier with significant cost-sharing requirements.
Wegovy and Zepbound: Semaglutide and Tirzepatide for Weight Loss
Wegovy (semaglutide, manufactured by Novo Nordisk) and Zepbound (tirzepatide, manufactured by Eli Lilly) are the two GLP-1 weight loss medications most likely to be covered by insurance when coverage exists at all. Both are FDA-approved specifically for chronic weight management in adults with obesity or overweight with at least one weight-related health condition.
When a plan does cover Wegovy and Zepbound, it almost always requires prior authorization. Coverage criteria typically include a BMI of 30 or higher, or a BMI of 27 or higher alongside a diagnosed condition such as type 2 diabetes, high blood pressure, or high cholesterol. Plans may also require documented prior attempts at diet and exercise, and some apply step therapy — meaning you may need to try and fail on a lower-cost medication before the insurer will approve a GLP-1.
For patients considering either medication, our guide Semaglutide vs. Tirzepatide for Weight Loss: Which Is Right for You? explains the clinical differences in detail.
Ozempic and Mounjaro: Coverage for Type 2 Diabetes vs. Weight Loss
Ozempic (semaglutide) and Mounjaro (tirzepatide) contain the same active ingredients as Wegovy and Zepbound but are FDA-approved for type 2 diabetes management, not obesity specifically. This distinction matters enormously for insurance purposes. Most plans that cover GLP-1 medications will cover Ozempic and Mounjaro when they are prescribed to treat type 2 diabetes — but will explicitly exclude the same drugs when prescribed primarily for weight loss.
Patients who have both obesity and type 2 diabetes are often in a better position for coverage, since the diabetes indication is more widely reimbursed. For those without a diabetes diagnosis, insurers may only approve the weight-loss-specific branded versions — Wegovy or Zepbound — and only if the plan includes obesity drug coverage at all.
If you are managing both conditions, our team also offers dedicated Diabetes Management in Houston and across all our Greater Houston locations.
What Insurance Plans Cover Weight Loss Medication?
Insurance coverage for weight loss medication is not uniform across plan types. Your specific situation — employer plan, Medicare, Medicaid, or a marketplace plan — determines what is available. Here is how each major category breaks down in 2026.
Employer-Sponsored Plans
Employer health plans are currently the most common source of GLP-1 insurance coverage for working-age adults. Some large employers — particularly those self-insuring under ERISA — have added Wegovy or Zepbound to their formularies as part of broader employee wellness strategies. However, many mid-size and smaller employers choose to exclude weight loss drugs entirely due to the cost impact on plan premiums.
If your employer’s plan excludes weight loss drugs, there is no appeals process that will override that exclusion — it is a plan design decision, not a coverage denial based on clinical criteria. The only options in that scenario are manufacturer savings programs, patient assistance programs, or GLP-1 bridge programs while seeking a plan that does include coverage.
Medicare Coverage for Weight Loss Medication
Standard Medicare Part D plans do not cover weight loss medication for obesity. This has been a long-standing coverage gap — Medicare’s rules historically barred coverage for obesity drugs specifically. However, Medicare does cover Ozempic and Mounjaro under Part D when they are prescribed for type 2 diabetes.
Medicare Advantage plans operate under different rules and a small number of Medicare Advantage plans have begun adding obesity medication coverage voluntarily. If you are on Medicare and need weight management support, it is worth reviewing your Medicare Advantage plan’s summary of benefits and coverage or calling your plan directly to ask about current formulary status.
There is active legislative discussion in 2026 about expanding Medicare coverage for GLP-1 weight loss medications, but as of this writing no federal mandate has passed. Your care provider can flag updates as coverage rules evolve.
Medicaid Coverage
Medicaid coverage for weight loss drugs varies by state. Some state Medicaid programs cover FDA-approved anti-obesity medications with prior authorization, while others exclude them entirely. Medicaid coverage tends to be more generous for patients who have a co-occurring diabetes diagnosis, since the diabetes indication is more widely reimbursed across state programs.
Texas Medicaid currently has limited coverage for GLP-1 weight loss medications outside of a diabetes indication. Patients should check their specific Medicaid managed care plan’s formulary, as coverage details differ between plans even within the same state program.
Which Insurance Companies Cover Weight Loss Drugs in 2026?
Coverage varies significantly even within the same insurer, since large carriers administer thousands of different employer group plans — each with its own formulary. The table below reflects general coverage trends based on published plan documentation and available formulary data as of mid-2026. Always confirm coverage details directly with your insurer and review your plan’s summary of benefits and coverage.
| Insurer | Wegovy / Zepbound | Ozempic / Mounjaro (T2D) | Notes |
| Blue Cross Blue Shield | Varies by plan | Generally covered | Some BCBS plans cover GLP-1s for obesity; varies by employer contract |
| UnitedHealthcare | Select plans only | Generally covered | Coverage requires prior auth; step therapy may apply |
| Aetna | Select employer plans | Generally covered | Aetna covers weight loss medication on some commercial plans with BMI criteria |
| Cigna | Select plans only | Generally covered | Commercial and employer plan coverage; exclusions common on individual plans |
| Humana | Limited coverage | Generally covered | Weight loss drug coverage limited outside employer-sponsored plans |
| Medicare Part D | Not covered | Covered for T2D | No Part D coverage for obesity indication; Medicare Advantage varies |
| Texas Medicaid | Very limited | Covered for T2D | GLP-1 coverage for weight loss only is rare under Texas Medicaid |
Health Insurance Coverage Landscape: Why So Many Plans Exclude Weight Loss Drugs
Understanding why insurers and employers choose to exclude weight loss drugs helps you set realistic expectations and advocate more effectively for coverage. There are three main reasons the coverage landscape remains fragmented.
First, cost. GLP-1 medications are among the most expensive drugs on the market. An insurer or employer that covers Wegovy or Zepbound for all eligible members faces a significant actuarial cost increase — which gets passed on as higher premiums across the group. Many plan sponsors have made a deliberate decision that the short-term cost is not justified by expected outcomes, even as clinical evidence continues to strengthen.
Second, durability questions. Some insurers are uncertain about what happens when patients stop taking these medications — clinical data shows that weight typically returns when GLP-1s are discontinued. Coverage for a medication that may be required indefinitely to maintain results is a different cost calculation from coverage for a short-term treatment course.
Third, prior frameworks. Medicare’s historical exclusion of obesity drugs treated obesity as a lifestyle issue rather than a chronic disease. That framing influenced employer plan design for decades. The recognition of obesity as a chronic disease deserving medical treatment — now the clinical consensus — has not yet been fully reflected in coverage policy at scale.
None of these barriers are permanent. Coverage is expanding, and patients who need treatment should not assume they have no options simply because their current plan excludes these medications.
Prior Authorization and Clinical Criteria for Weight Loss Medication
Even when a plan does cover weight loss medication, approval is not automatic. Prior authorization is the standard requirement — meaning your prescriber must submit clinical documentation to the insurer before the medication will be covered. Understanding the criteria involved helps you prepare.
Most plans that cover GLP-1 weight loss medications apply at least some of the following criteria:
- BMI of 30 or higher (obesity), or BMI of 27 or higher with at least one weight-related comorbidity
- Documented diagnosis of a qualifying comorbidity: type 2 diabetes, high blood pressure, high cholesterol, or obstructive sleep apnea
- Evidence of prior attempts at lifestyle intervention — typically structured diet and exercise programs — without sufficient weight loss
- Prescription from a qualifying care provider (not all plans accept prescriptions from all provider types)
- No contraindications to the specific medication requested
- Step therapy compliance, if required — meaning a trial of a lower-cost medication first
Your physician plays a critical role in the prior authorization process. Accurate documentation of your obesity diagnosis, comorbid conditions, and prior treatment history significantly affects the outcome. A well-prepared prior authorization submission — including a letter of medical necessity where appropriate — is much more likely to be approved on the first submission than an incomplete one.
If your prior authorization is denied, you have the right to appeal. Your physician can provide additional clinical documentation, reference published clinical guidelines, or request a peer-to-peer review with the insurer’s medical director. Many initial denials are overturned on appeal when the clinical case is presented thoroughly.
For a detailed guide on GLP-1 dosing and how these medications work, see our article GLP-1 Semaglutide Dosage for Weight Loss: The Complete Dosing Guide.
How to Get Insurance Coverage for Weight Loss Medication
If you want to give yourself the best chance of getting your weight loss medication covered by insurance, the process works best when you and your physician approach it systematically. Here is a step-by-step path.
Step 1: Confirm Your Plan’s Formulary
Start by calling your insurer or reviewing your plan’s summary of benefits and coverage online. Ask specifically whether GLP-1 weight loss medications are included on the formulary, which tier they are placed on, and whether prior authorization is required. Also ask whether your plan applies a step therapy requirement. Having your insurance card on hand when you call speeds this process.
Step 2: Have Your Clinical Criteria Documented
Work with your physician to document your BMI, any obesity-related health conditions, and your prior attempts at weight management. This documentation forms the foundation of any prior authorization request. If your BMI is just below 30, your physician may still be able to make a case if you have qualifying comorbidities.
Step 3: Submit Prior Authorization with Full Clinical Support
Your prescriber’s office will submit the prior authorization request. Provide as much clinical history as possible — including any prior medications tried, structured weight loss programs attempted, and relevant lab results. If your insurer requires a specific form, confirm that your prescriber has the most current version.
Step 4: Appeal a Denial if Necessary
If coverage is denied, do not accept the denial without reviewing the reason. Common denial reasons include missing documentation, unmet step therapy requirements, or a BMI that does not meet the plan’s threshold. Each of these can potentially be addressed in an appeal. Ask your physician to write a letter of medical necessity and, if warranted, to request a peer-to-peer review.
Step 5: Explore a GLP-1 Bridge Program if Needed
If insurance approval is taking time or has been denied, both Novo Nordisk and Eli Lilly offer patient savings and assistance programs. A GLP-1 bridge program — short-term manufacturer-supported access while a coverage decision is pending or appealed — can help patients avoid an interruption in treatment. Ask your physician about current program availability, as terms change.
Patients managing their weight as part of diabetes care may also benefit from our guide on How to Manage Type 2 Diabetes Without Medication, which covers lifestyle approaches that complement medical treatment.
Medical Weight Loss at Core Primary Care in Houston
At Core Primary Care, our physicians approach weight management as a chronic disease — not a lifestyle issue. That means treating obesity with the same clinical rigor applied to hypertension or type 2 diabetes: appropriate diagnosis, evidence-based medication where indicated, and ongoing follow-up to track outcomes and adjust treatment.
Our medical weight loss program includes physician evaluation, BMI and metabolic assessment, GLP-1 medication prescribing where appropriate, insurance navigation support, and ongoing weight management monitoring. For patients in Houston, Sugar Land, Katy, and Needville, we are available for in-person visits as well as telemedicine appointments where appropriate.
Our team is experienced with the prior authorization process for semaglutide and tirzepatide and can help build the clinical documentation needed to support a successful coverage request. If your insurer requires step therapy, we can also work with you on that path — prescribing the required intermediate medication while building the case for GLP-1 approval.
Learn more about our Semaglutide for Weight Loss and Tirzepatide for Weight Loss programs, or explore our full GLP-1 Medications for Weight Loss service page.
When to Talk to a Doctor About Weight Loss Medication
You do not need to have already tried and failed at every diet before speaking with a physician about medical weight loss. If your BMI is 30 or higher, or 27 or higher with a condition like type 2 diabetes or high blood pressure, you are already in the clinical range where FDA-approved weight loss medication may be appropriate.
A primary care physician is the right starting point. They can assess your full health picture, review your insurance coverage, order baseline labs, and prescribe a GLP-1 medication if it is clinically appropriate. They can also submit prior authorization on your behalf and help you appeal if coverage is initially denied.
Core Primary Care sees patients for weight management consultations at all four of our Greater Houston locations. If you prefer to start with a virtual visit, telemedicine appointments are available for initial consultations.
Frequently Asked Questions
Does insurance cover weight loss medication in 2026?
Coverage depends on your specific plan. Employer-sponsored health plans are the most likely source of GLP-1 coverage for working-age adults, and more plans have been adding Wegovy and Zepbound to their formularies as clinical evidence grows. However, many plans — including standard Medicare Part D and a large share of individual market plans — still exclude weight loss drugs. The safest approach is to call your insurer directly and ask about your current formulary, prior authorization requirements, and any step therapy policies that apply.
What insurance covers Wegovy for weight loss?
Wegovy is covered by a growing number of large employer health plans, including some plans administered by Blue Cross Blue Shield, UnitedHealthcare, Aetna, and Cigna. Coverage under each of these insurers varies by the specific employer group plan, since insurers administer thousands of different plan designs. Medicare Part D does not cover Wegovy for weight loss. Select Medicare Advantage plans may offer coverage — check your plan’s summary of benefits. Medicaid coverage for Wegovy is available in some states but is very limited in Texas.
Is tirzepatide covered by insurance?
Tirzepatide is covered under two brand names: Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management). Most major insurers cover Mounjaro for patients with a type 2 diabetes diagnosis. Zepbound coverage for weight loss only is less consistent and tends to follow the same employer plan patterns as Wegovy. Prior authorization is required in virtually all cases, and BMI criteria and comorbidity requirements typically apply.
Does Medicare cover weight loss medication?
Standard Medicare Part D does not cover weight loss drugs for obesity. This has been a long-standing gap in Medicare coverage. However, Medicare does cover Ozempic and Mounjaro when prescribed for type 2 diabetes management under Part D. A small number of Medicare Advantage plans have voluntarily added obesity medication coverage — check your specific plan’s formulary. Legislative changes that would expand Medicare Part D to cover GLP-1 weight loss medications have been proposed but not enacted as of mid-2026.
How can I get my insurance to cover Ozempic or semaglutide for weight loss?
If your plan covers GLP-1 medications for weight loss, your physician will need to submit a prior authorization request with clinical documentation supporting your eligibility. This typically includes your BMI, any weight-related health conditions, and evidence of prior lifestyle interventions. If your plan covers Ozempic or semaglutide only for type 2 diabetes, you would need a confirmed diabetes diagnosis for coverage to apply. If denied, you can appeal — ask your physician for a letter of medical necessity and consider requesting a peer-to-peer review.
What is prior authorization for weight loss medication?
Prior authorization is a process where your physician submits clinical information to your insurer before a prescription is approved for coverage. For weight loss medication, this typically means documenting your BMI, relevant health conditions like type 2 diabetes or high blood pressure, and prior attempts at diet and exercise. The insurer reviews this information against their coverage criteria and either approves or denies the request. Prior authorization is required by almost all plans that cover GLP-1 weight loss medications and can take several days to a few weeks to process.
Does Medicaid cover weight loss drugs in Texas?
Texas Medicaid has very limited coverage for GLP-1 medications used specifically for weight loss. Medicaid managed care plans in Texas are more likely to cover GLP-1 drugs like Ozempic or Mounjaro for patients who have a type 2 diabetes diagnosis, since the diabetes indication has broader reimbursement support. Patients on Texas Medicaid should review their specific managed care plan’s formulary or call their plan to confirm current coverage details, as formularies are updated regularly.
What does ‘step therapy’ mean for weight loss medication coverage?
Step therapy is an insurer requirement that you try one or more lower-cost medications before they will approve a more expensive drug. For weight loss medication, this may mean trialing an oral medication like Contrave or Qsymia before an insurer will approve Wegovy or Zepbound. If the lower-cost medication does not produce adequate results or causes side effects, that outcome is then documented to support approval of the preferred GLP-1. Your physician can guide you through step therapy requirements and document the process appropriately.
How much does Wegovy or Zepbound cost without insurance?
Without insurance coverage, the out-of-pocket cost for Wegovy or Zepbound is typically $1,000 to $1,400 per month at standard retail pharmacy prices. Both Novo Nordisk and Eli Lilly offer manufacturer savings programs that can reduce out-of-pocket costs for commercially insured patients who do not meet their plan’s coverage criteria. Patient assistance programs may be available for uninsured patients who meet income criteria. Ask your physician or contact the manufacturer directly for current program details, as terms and availability change.
Key Takeaways
- Weight loss drugs covered by insurance include FDA-approved GLP-1 medications like Wegovy and Zepbound — but coverage is highly inconsistent across plan types.
- Employer-sponsored plans are the most likely source of coverage for working-age adults in 2026; standard Medicare Part D does not cover GLP-1s for weight loss.
- Prior authorization is required by virtually all plans that do cover these medications; clinical criteria typically include BMI of 30+, or BMI 27+ with a qualifying condition.
- Ozempic and Mounjaro are widely covered for type 2 diabetes but are often excluded when prescribed for weight loss as a standalone indication.
- If your insurer denies coverage, you have the right to appeal — physician documentation and a letter of medical necessity significantly improve outcomes.
- Step therapy, formulary tier placement, and employer plan design decisions can all affect whether your specific medication is covered.
- Core Primary Care physicians in Houston, Sugar Land, Katy, and Needville can evaluate your eligibility, prescribe GLP-1 medications where appropriate, and help navigate the prior authorization process.
| Start Your Medical Weight Loss Program at Core Primary Care Insurance coverage for weight loss drugs changes — but your physician-supervised program doesn’t have to wait. Core Primary Care helps patients in Houston, Sugar Land, Katy, and Needville navigate coverage, prior authorization, and GLP-1 access. Book an appointment and take the first step today. Find your nearest location: Weight Loss in Houston | Weight Loss in Sugar Land | Weight Loss in Katy | Weight Loss in Needville |